First Trust Advisors LP Has $59.86 Million Stake in Corcept Therapeutics Incorporated $CORT

First Trust Advisors LP raised its stake in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) by 34.1% in the 3rd quarter, Holdings Channel reports. The firm owned 720,224 shares of the biotechnology company’s stock after purchasing an additional 183,038 shares during the quarter. First Trust Advisors LP’s holdings in Corcept Therapeutics were worth $59,858,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Clearstead Advisors LLC grew its position in shares of Corcept Therapeutics by 163.6% in the 3rd quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company’s stock valued at $26,000 after buying an additional 193 shares during the last quarter. Hantz Financial Services Inc. raised its position in shares of Corcept Therapeutics by 598.5% during the third quarter. Hantz Financial Services Inc. now owns 461 shares of the biotechnology company’s stock worth $38,000 after acquiring an additional 395 shares during the last quarter. Employees Retirement System of Texas bought a new position in shares of Corcept Therapeutics during the second quarter worth about $52,000. Bessemer Group Inc. lifted its stake in shares of Corcept Therapeutics by 119.2% in the third quarter. Bessemer Group Inc. now owns 629 shares of the biotechnology company’s stock worth $53,000 after acquiring an additional 342 shares during the period. Finally, Salomon & Ludwin LLC bought a new stake in Corcept Therapeutics in the third quarter valued at approximately $56,000. 93.61% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, insider William Guyer sold 8,233 shares of the company’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $35.99, for a total transaction of $296,305.67. Following the transaction, the insider owned 2,231 shares in the company, valued at approximately $80,293.69. This represents a 78.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 48,233 shares of company stock valued at $1,817,306 over the last ninety days. Insiders own 20.50% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on CORT shares. HC Wainwright decreased their target price on shares of Corcept Therapeutics from $105.00 to $67.00 and set a “buy” rating for the company in a research report on Friday, February 20th. UBS Group assumed coverage on shares of Corcept Therapeutics in a research note on Tuesday, December 16th. They issued a “neutral” rating and a $95.00 price objective on the stock. Zacks Research cut shares of Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 13th. Weiss Ratings reissued a “hold (c)” rating on shares of Corcept Therapeutics in a research note on Monday, December 29th. Finally, Wolfe Research lowered shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 target price on the stock. in a report on Wednesday, December 31st. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $77.17.

Trending Headlines about Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Neutral Sentiment: Short‑interest reports for early March show anomalous zero/NaN values and appear unreliable; there’s no clear evidence of a material short squeeze or buildup from the published figures. Short Interest Details
• Negative Sentiment: Holzer & Holzer filed an investor class action alleging Corcept made false/misleading statements and omitted material facts about relacorilant clinical trials and the odds of FDA approval — a direct legal claim tied to the company’s core drug program that could lead to damages, discovery of internal documents, and management distraction. Holzer & Holzer Investor Alert
• Negative Sentiment: Multiple plaintiff firms (Hagens Berman, Pomerantz, Bernstein Liebhard, Schall, Bragar Eagel & Squire, others) have announced or are soliciting participants in the same or related securities suits covering Oct 31, 2024–Dec 30, 2025 — the proliferation of firms increases filing activity and the chance of consolidated, high‑stakes litigation. Hagens Berman Alert
• Negative Sentiment: Business Wire and other notices remind investors of the April 21, 2026 lead‑plaintiff deadline — concentrated deadlines typically accelerate filings and media attention and can drive short‑term selling as investors price in legal uncertainty. Business Wire Reminder
• Negative Sentiment: Additional firm notices (PR Newswire, Law Offices of Howard G., Rosen, The Gross Law Firm, DJS Law Group, etc.) amplify outreach and may increase the probability of class consolidation and settlement pressure on Corcept. Investors should monitor filings, any company responses, and potential disclosures about trial data or internal communications. PR Newswire: Litigation Notice

Corcept Therapeutics Price Performance

Corcept Therapeutics stock opened at $33.54 on Wednesday. The stock has a market capitalization of $3.57 billion, a price-to-earnings ratio of 40.90 and a beta of 0.29. Corcept Therapeutics Incorporated has a 52-week low of $28.66 and a 52-week high of $117.33. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.85 and a current ratio of 2.92. The stock’s 50 day moving average price is $37.94 and its two-hundred day moving average price is $63.87.

Corcept Therapeutics (NASDAQ:CORT) last released its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $0.20 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.13). The company had revenue of $202.13 million during the quarter, compared to the consensus estimate of $254.94 million. Corcept Therapeutics had a net margin of 12.96% and a return on equity of 15.19%. The business’s revenue was up 11.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.26 EPS. On average, equities analysts predict that Corcept Therapeutics Incorporated will post 1.36 earnings per share for the current year.

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.